Clinical Trial Update: Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating reduced-dose pomalidomide and cyclophosphamide with dexamethasone for relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: UNKNOWN